Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Patients' perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate: A qualitative interview study
NTNU - Norges teknisk-naturvitenskapelige universitet, Norway.
Psykiatrisk Center Sct. Hans, Denmark.
Ersta Sköndal Bräcke University College, Department of Health Care Sciences.ORCID iD: 0000-0003-4021-2393
Jönköping University.
Show others and affiliations
2021 (English)In: Nordic Journal of Psychiatry, ISSN 0803-9488, E-ISSN 1502-4725, Vol. 75, no 4, p. 257-265Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: Three-monthly dosage of paliperidone palmitate entails longer time to relapse after discontinuation, is similarly tolerable and safe compared to monthly injections of paliperidone palmitate and is beneficial for the caregivers. However, few studies have so far explored in depth the patients' experiences with paliperidone palmitate medication every three months, or with switching from monthly to three-monthly injections of paliperidone palmitate.

MATERIAL AND METHODS: A qualitative study based on individual interviews with persons with schizophrenia who receive three-monthly paliperidone palmitate in Norway, Sweden and Denmark. Data was analysed according to qualitative content analysis.

RESULTS: Twenty-four patients, 16 men and 8 women, took part in individual interviews. The patients' mental health care professionals mainly recommended the switch to three-monthly paliperidone palmitate, and few or no disadvantages were described. According to the patients, three-monthly paliperidone palmitate had several advantages, such as less frequent injections, less administration and planning and less focus on the illness. In addition, the participants described feeling more stability, being more physically and socially active, and that improvement processes were supported. For some, the use involved practical and economic challenges, and some worried whether the medicine 'wore off' before the next injection. According to the patients, switching to three-monthly paliperidone palmitate did not influence the frequency or content of patients' interaction with health care professionals.

CONCLUSION: Switching from monthly to three-monthly injections with paliperidone palmitate seems to be experienced as advantageous for patients with schizophrenia.

Place, publisher, year, edition, pages
2021. Vol. 75, no 4, p. 257-265
Keywords [en]
Psychiatry, Antipsychotic medication, Long-term antipsychotic injections, Mental health, Paliperidone palmitate, Schizophrenia, Service user perspectives
National Category
Psychiatry Nursing
Identifiers
URN: urn:nbn:se:esh:diva-8453DOI: 10.1080/08039488.2020.1841289PubMedID: 33151121OAI: oai:DiVA.org:esh-8453DiVA, id: diva2:1505517
Available from: 2020-12-01 Created: 2020-12-01 Last updated: 2023-01-26Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Erdner, Anette

Search in DiVA

By author/editor
Erdner, Anette
By organisation
Department of Health Care Sciences
In the same journal
Nordic Journal of Psychiatry
PsychiatryNursing

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 50 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf